Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 304

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 304
---
DEFICIT)

(in thousands, except share amounts) 

(Unaudited)

Series SeedSeries ASeries BSeries C Common Stock AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitTotalStockholders’Equity (Deficit)Preferred Stock Preferred StockPreferred Stock Preferred Stock SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 20243,963,96313,0145,704,16125,23511,370,621110,79118,628,970181,3284,722,763517,000368(181,086)$(163,713)Conversion of convertible preferred stock to common stock upon closing of initial public offering(3,963,963)(13,014)(5,704,161)(25,235)(11,370,621)(110,791)(18,628,970)(181,328)27,149,20627 330,340 — — 330,367 Issuance of common stock from initial public offering, net of issuance costs of $4,265—— —— —— —— 12,176,46712 199,558 — — 199,570 Vesting of restricted common stock awards—— —— —— —— 43,681— — — — — Stock-based compensation expense—— —— —— —— —— 2,094 — — 2,094 Unrealized loss on marketable securities—— —— —— —— —— — (67)— (67)Net loss—— —— —— —— —— — — (16,482)(16,482)Balance at March 31, 2025—$— —$— —$— —$— 44,092,117$44 $548,992 $301 $(197,568)$351,769 Exercise of common stock options————————7,944—6——6 Vesting of restricted common stock awards————————32,277————— Stock-based compensation expense——————————2,840——2,840 Unrealized loss on marketable securities———————————(118)—(118)Net loss————————————(18,068)(18,068)Balance at June 30, 2025—$— —$— —$— —$— 44,132,338$